New vaccine combo takes on Hard-to-Treat sarcomas
NCT ID NCT07648069
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This early-stage trial tests a custom-made vaccine (SarcVac) designed from each patient's tumor mutations, combined with immune-boosting cells and a PD-1 antibody. It enrolls 16 adults with advanced bone or soft tissue sarcoma that did not respond to first-line treatment. The main goal is to see if the combination is safe and tolerable, with a secondary look at whether it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized tumor neoantigen vaccine (SarcVac) combined with tumor-specific lymphocytes and an anti-PD1 antibody
What this could lead to
If successful, this could point toward a new treatment option for advanced sarcoma patients who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) and small trial with only 16 participants, so it is mainly checking safety. The treatment may not shrink tumors or work for everyone, and side effects from the vaccine and immune therapy are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.